Boston Scientific Corporation (BSX) (Q2FY23)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments.
The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems.
In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer.
In recent quarters, Boston Scientific has experienced favorable outcomes due to an increase in elective procedure volume. The acquisition of Baylis Medical in Q1FY22 is expected to contribute positively to the company’s revenue growth in FY23.
Boston Scientific Corporation stock price showed a volatile trend in past 3-months. It declined by 1.59% during the period. The stock price increased by 23.89% in past 1-year. The stock has a 52-week high of $54.75 and its 52-week low is $37.74.
In the past 3 years, the stock has given returns of 30.15%. BSX has a 50-day moving Avg. and 200-day moving Avg. of $52.36 and $48.61, respectively.
This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals
– Price Performance
Stock Price Performance
No of Pages: 34
To download the previous quarter’s equity report CLICK HERE
To Download other equity/ stock reports CLICK HERE
Follow our LinkedIn page for more updates